Overview

Molecular Signatures of Cutaneous Dupilumab Response

Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco